EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide.
Reasonable growth potential with adequate balance sheet.
Share Price & News
How has EDAP TMS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EDAP's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: EDAP exceeded the US Medical Equipment industry which returned 12.7% over the past year.
Return vs Market: EDAP exceeded the US Market which returned 10.5% over the past year.
Price Volatility Vs. Market
How volatile is EDAP TMS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
15 hours ago | Simply Wall StBefore You Buy EDAP TMS S.A. (NASDAQ:EDAP), Consider Its Volatility
3 weeks ago | Simply Wall StA Closer Look At EDAP TMS S.A.'s (NASDAQ:EDAP) Impressive ROE
1 month ago | Simply Wall StDo EDAP TMS S.A.’s (NASDAQ:EDAP) Returns On Capital Employed Make The Cut?
Is EDAP TMS undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EDAP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EDAP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EDAP is good value based on its PE Ratio (30.6x) compared to the Medical Equipment industry average (44.9x).
PE vs Market: EDAP is poor value based on its PE Ratio (30.6x) compared to the US market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: EDAP is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: EDAP is overvalued based on its PB Ratio (4.3x) compared to the US Medical Equipment industry average (4x).
How is EDAP TMS forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDAP's forecast earnings growth (28.7% per year) is above the savings rate (1.7%).
Earnings vs Market: EDAP's earnings (28.7% per year) are forecast to grow faster than the US market (13.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EDAP's revenue (9.9% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: EDAP's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDAP's Return on Equity is forecast to be high in 3 years time
How has EDAP TMS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDAP has a high level of non-cash earnings.
Growing Profit Margin: EDAP became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: EDAP has become profitable over the past 5 years, growing earnings by 8.7% per year.
Accelerating Growth: EDAP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EDAP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).
Return on Equity
High ROE: EDAP's Return on Equity (14.1%) is considered low.
How is EDAP TMS's financial position?
Financial Position Analysis
Short Term Liabilities: EDAP's short term assets (€40.4M) exceed its short term liabilities (€16.8M).
Long Term Liabilities: EDAP's short term assets (€40.4M) exceed its long term liabilities (€7.0M).
Debt to Equity History and Analysis
Debt Level: EDAP's debt to equity ratio (22.1%) is considered satisfactory.
Reducing Debt: EDAP's debt to equity ratio has reduced from 27.3% to 22.1% over the past 5 years.
Inventory Level: EDAP has a high level of physical assets or inventory.
Debt Coverage by Assets: EDAP's debt is covered by short term assets (assets are 7.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDAP is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: Insufficient data to determine if EDAP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is EDAP TMS's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EDAP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDAP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDAP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDAP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Marc Oczachowski (49yo)
Mr. Marc Oczachowski has been Chief Executive Officer of EDAP TMS SA since March 31, 2007 and its Executive Director since July 1, 2017. Mr. Oczachowski serves as the President of EDAP TMS France SAS and E ...
|CEO & Executive Director||12.9yrs||no data||no data|
|Independent Director||10.7yrs||no data||no data|
|Independent Chairman of the Board||22.8yrs||no data||no data|
|Independent Director||17.4yrs||no data||no data|
|Independent Director||10.6yrs||no data||no data|
Experienced Board: EDAP's board of directors are seasoned and experienced ( 10.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EDAP TMS S.A.'s company bio, employee growth, exchange listings and data sources
- Name: EDAP TMS S.A.
- Ticker: EDAP
- Exchange: NasdaqGM
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$115.991m
- Shares outstanding: 29.00m
- Website: https://www.edap-tms.com
Number of Employees
- EDAP TMS S.A.
- Parc d’Activites la Poudrette-Lamartine
- 4/6, rue du Dauphiné
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EDAP||NasdaqGM (Nasdaq Global Market)||Yes||ADS EACH REPR 1 ORD SHARE FRF0.8||US||USD||Aug 1997|
|EDA||DB (Deutsche Boerse AG)||Yes||ADS EACH REPR 1 ORD SHARE FRF0.8||DE||EUR||Aug 1997|
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company’s proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move and the Sonolith i-sys lithotripters for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. It also leases lithotripters; and sells disposables, spare parts, and maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 23:36|
|End of Day Share Price||2020/02/26 00:00|